The CDC has reported that the monovalent mRNA vaccine is 76% effective at preventing COVID-19-related invasive mechanical ventilation and death up to 6 months after the last dose, and 56% effective for at least a year after. The FDA has authorized the use of a bivalent mRNA vaccine for primary and future doses. The American Heart Association provides resources to promote vaccine confidence. The CDC recommends that all eligible individuals receive the vaccine, including the updated bivalent vaccine, to prevent critical outcomes of COVID-19.
The Centers for Disease Control and Prevention (CDC) recently reported the effectiveness of the COVID-19 vaccine against the Omicron variant, which was predominant between February 2022 and February 2023. The study showed that monovalent mRNA vaccination was 76% effective in preventing COVID-19-associated invasive mechanical ventilation and death for up to 6 months after the last dose. Moreover, it was found to be 56% effective at least one year after the last dose.
In addition, the Food and Drug Administration (FDA) recently authorized the use of a single dose of bivalent mRNA COVID-19 vaccine for primary vaccination as well as for future doses. The updated bivalent vaccine includes the genetic codes for the Omicron and Delta variants.
Despite the effectiveness of the COVID-19 vaccine, there are still some people who are hesitant to get vaccinated due to misinformation, concerns about side effects, or other reasons. To promote vaccine confidence, the American Heart Association (AHA) provides resources and information on the benefits and safety of the COVID-19 vaccine.
It is important to note that the COVID-19 vaccine is the most effective tool to prevent severe illness, hospitalization, and death from COVID-19. The CDC recommends that all eligible individuals receive the vaccine, including the updated bivalent vaccine, to prevent critical outcomes of COVID-19.
Leave a Reply